FINWIRES · TerminalLIVE
FINWIRES

PharmaCorp Rx Acquires Eight Pharmacies For $24.2 Million

作者

-- PharmaCorp Rx (PCRX.V) on Thursday said it agreed to acquire eight PharmaChoice Canada-bannered pharmacies in Eastern Canada for $24.2 million.

The acquisitions, which will be financed with existing cash on hand, expands PharmaCorp's geographical footprint and operating scale, a statement said. All locations will continue to be operated by their existing managing pharmacists.

The acquisitions are expected to close within 60 days.

PharmaCorp also signed non-binding letters to acquire four morel pharmacies, which, if completed, are expected to close over the next two quarters.

"The acquisitions reflect the continued execution of our acquisition strategy and the strength of our sourcing network," said executive chair Alan Simpson. "The clustering of these locations within a key urban market, combined with the continuity of experienced managing pharmacists, positions us to integrate efficiently while maintaining strong local relationships and operating performance. We are seeing an increasing number of acquisition opportunities where we are engaged early in the process, allowing us to selectively pursue acquisitions that align with our disciplined approach to valuation, integration, and long-term value creation."

PharmaCorp shares closed up $0.07 to $0.50 on the TSX Venture Exchange.

相关文章

Asia

瑞思迈公布第三财季非GAAP盈利和营收均有所增长

瑞思迈(ResMed,ASX:RMD)周五公布了2026财年第三季度非GAAP每股收益为2.86澳元,高于去年同期的2.37澳元。 FactSet调查的分析师此前预期每股收益为2.80澳元。 截至3月31日的三个月内,公司营收为14.3亿澳元,高于去年同期的12.9亿澳元。FactSet调查的分析师此前预期营收为14.2亿澳元。 公司预计2026财年非GAAP毛利率将在62%至63%之间。 董事会宣布派发季度股息,每股0.60澳元,高于去年同期的0.53澳元,将于6月18日支付给截至5月14日登记在册的股东。

$ASX:RMD
Research

研究快讯:Bio:尽管销售额/利润率大幅下降,但第一季度业绩仍高于预期

独立研究机构CFRA向提供了以下研究报告。CFRA分析师总结如下:BIO公布的第一季度业绩显示,其两大业务板块均面临压力。营收为5.921亿美元,同比增长1.1%(比市场预期高出约300万美元),但按固定汇率计算下降4.2%。调整后每股收益为1.89美元,同比下降25.6%,但比市场预期高出0.10美元。营业利润率从上年同期的10.8%下降420个基点至6.6%。生命科学和临床诊断业务板块均出现按固定汇率计算的下滑,主要原因是学术界持续疲软以及中东冲突的影响。管理层下调了2026年业绩预期,预计按固定汇率计算,营收增长率为-3.0%至+0.5%(此前预期为+0.5%至+1.5%),营业利润率为10.0%至12.0%(此前预期为12.0%至12.5%)。尽管面临运营方面的挑战,BIO仍保持了强劲的现金流,自由现金流达7810万美元,并回购了约17.6万股股票。我们认为,公司资产负债表依然稳健,拥有15.6亿美元的现金和短期投资,这使其在充满挑战的市场环境下仍具备财务灵活性。

$BIO
Research

研究快讯:Arthur J. Gallagher 第一季度收购相关收入强劲增长

独立研究机构CFRA向提供了以下研究报告。CFRA分析师的观点总结如下:AJG第一季度调整后每股收益为4.47美元,高于去年同期的3.72美元,低于我们此前4.56美元的预期,但高于市场普遍预期的4.43美元。第一季度营收增长28%,超过我们此前12%-18%的预期,主要得益于收购,但公司整体5%的内生增长低于我们此前7%-10%的预期。我们认为AJG是业内整合能力较强的公司之一,但投资者对这种收购策略固有的执行风险日益担忧。管理层依然保持乐观,并强调本季度是AJG连续第24个季度实现两位数的调整后EBITDAC增长。第一季度利润率表现喜忧参半。受上年同期AssuredPartners融资收益的影响,经纪业务调整后EBITDAC利润率下降320个基点至40.1%;而风险管理业务利润率则上升130个基点至21.7%。AJG第一季度完成9项收购,总价值5900万美元,而上年同期完成11项收购,总价值1.01亿美元。我们预计,收购仍将是AJG未来增长战略的核心。

$AJG